PolyMedix has said that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity in an in vitro laboratory test against the New Delhi metallo-beta-lactamase-1 (NDM-1) drug resistant strain of Klebsiella pneumonia.
The drug candidate is currently undergoing Phase II trial in patients with acute bacterial skin and skin structure infections that are caused by Staphylococcus bacteria.
The anti-inflammatory properties of PolyMedix's defensin-mimetic compound may benefit in the treatment of several infectious disorders and have distinct characteristics against other antibiotic agents.
PolyMedix President and CEO Nicholas Landekic said NDM-1 resistant bacteria are a growing concern to the medical community.
NDM-1 is an enzyme carried by bacteria resistant to antibiotics.